Coherus and Junshi Announce Positive Interim Results from Phase 3 CHOICE-01 Trial of Toripalimab Chemotherapy Combination for 1st-Line Non-Small Cell Lung Cancer

Coherus and Junshi Announce Positive Interim Results from Phase 3 CHOICE-01 Trial of Toripalimab Chemotherapy Combination for 1st-Line Non-Small Cell Lung Cancer

Coherus Biosciences and Junshi Biosciences announced positive interim from the phase 3 CHOICE-01 trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival (PFS) per RECIST v1.1 compared to chemotherapy alone. The results will be summarized September 13 in an oral presentation by Professor Jie Wang, MD, PhD, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, during the Mini Oral Session at the 2021 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC). 

The randomized, double-blind, placebo-controlled trial enrolled 465 treatment-naive advanced NSCLC patients (220 squamous and 245 non-squamous) who were randomized (2:1) to toripalimab plus chemotherapy or placebo plus chemotherapy.  The primary endpoint of PFS was ass...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee